LT3672571T - Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą - Google Patents
Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidąInfo
- Publication number
- LT3672571T LT3672571T LTEPPCT/IB2018/056281T LTIB2018056281T LT3672571T LT 3672571 T LT3672571 T LT 3672571T LT IB2018056281 T LTIB2018056281 T LT IB2018056281T LT 3672571 T LT3672571 T LT 3672571T
- Authority
- LT
- Lithuania
- Prior art keywords
- phenyl
- dimorpholin
- triazin
- piperidin
- dimethylamino
- Prior art date
Links
- DWZAEMINVBZMHQ-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CCOCC2)N2CCOCC2)C=C1 DWZAEMINVBZMHQ-UHFFFAOYSA-N 0.000 title 1
- 239000013011 aqueous formulation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550007P | 2017-08-25 | 2017-08-25 | |
| US201862681720P | 2018-06-07 | 2018-06-07 | |
| US201862703022P | 2018-07-25 | 2018-07-25 | |
| PCT/IB2018/056281 WO2019038657A1 (en) | 2017-08-25 | 2018-08-20 | AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING 1- (4 - {[4- (DIMETHYLAMINO) PIPERIDIN-1-YL] CARBONYL} PHENYL) -3- [4- (4,6-DIMORPHOLIN-4-YL-1,3,5) triazin-2-yl) phenyl] urea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3672571T true LT3672571T (lt) | 2021-12-10 |
Family
ID=63586769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/IB2018/056281T LT3672571T (lt) | 2017-08-25 | 2018-08-20 | Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11541058B2 (lt) |
| EP (1) | EP3672571B1 (lt) |
| JP (1) | JP7313126B2 (lt) |
| CY (1) | CY1124820T1 (lt) |
| ES (1) | ES2895370T3 (lt) |
| HR (1) | HRP20211985T1 (lt) |
| HU (1) | HUE056743T2 (lt) |
| LT (1) | LT3672571T (lt) |
| PL (1) | PL3672571T3 (lt) |
| PT (1) | PT3672571T (lt) |
| RS (1) | RS62663B1 (lt) |
| SI (1) | SI3672571T1 (lt) |
| TW (1) | TW201919635A (lt) |
| WO (1) | WO2019038657A1 (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2956225T3 (es) * | 2018-06-07 | 2023-12-15 | Pfizer | Formulación acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea |
| AU2022320615A1 (en) | 2021-07-26 | 2024-03-14 | Celcuity Inc. | 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI109332B (fi) | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Toremifeenin liukoisia koostumuksia |
| CA2472342A1 (en) | 2002-01-30 | 2003-08-07 | Pfizer Products Inc. | Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide |
| JP2011520979A (ja) | 2008-05-23 | 2011-07-21 | ワイス・エルエルシー | ＰＩ３キナーゼおよびｍＴＯＲ阻害剤としてのトリアジン化合物 |
| US10022381B2 (en) | 2008-05-23 | 2018-07-17 | Pfizer Inc. | Triazine compounds as PI3 kinase and mTOR inhibitors |
| WO2010096619A1 (en) | 2009-02-23 | 2010-08-26 | Wyeth Llc | Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
| US20140220112A1 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| PL3116547T3 (pl) | 2014-03-14 | 2019-11-29 | Pfizer | Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania |
| DK3233054T3 (da) | 2014-12-17 | 2021-08-02 | Pfizer | Formuleringer af en PI3K/MTOR-hæmmer til intravenøs administration |
| ES2956225T3 (es) | 2018-06-07 | 2023-12-15 | Pfizer | Formulación acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea |
-
2018
- 2018-08-20 LT LTEPPCT/IB2018/056281T patent/LT3672571T/lt unknown
- 2018-08-20 EP EP18769793.3A patent/EP3672571B1/en active Active
- 2018-08-20 PT PT187697933T patent/PT3672571T/pt unknown
- 2018-08-20 HR HRP20211985TT patent/HRP20211985T1/hr unknown
- 2018-08-20 WO PCT/IB2018/056281 patent/WO2019038657A1/en unknown
- 2018-08-20 PL PL18769793T patent/PL3672571T3/pl unknown
- 2018-08-20 SI SI201830492T patent/SI3672571T1/sl unknown
- 2018-08-20 ES ES18769793T patent/ES2895370T3/es active Active
- 2018-08-20 HU HUE18769793A patent/HUE056743T2/hu unknown
- 2018-08-20 US US16/641,045 patent/US11541058B2/en active Active
- 2018-08-20 RS RS20211487A patent/RS62663B1/sr unknown
- 2018-08-22 JP JP2018155174A patent/JP7313126B2/ja active Active
- 2018-08-22 TW TW107129306A patent/TW201919635A/zh unknown
-
2021
- 2021-12-20 CY CY20211101116T patent/CY1124820T1/el unknown
-
2022
- 2022-11-30 US US18/072,246 patent/US20230218628A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CY1124820T1 (el) | 2022-11-25 |
| TW201919635A (zh) | 2019-06-01 |
| RS62663B1 (sr) | 2021-12-31 |
| EP3672571B1 (en) | 2021-10-06 |
| HUE056743T2 (hu) | 2022-03-28 |
| WO2019038657A1 (en) | 2019-02-28 |
| HRP20211985T1 (hr) | 2022-04-01 |
| SI3672571T1 (sl) | 2022-01-31 |
| US20230218628A1 (en) | 2023-07-13 |
| PL3672571T3 (pl) | 2022-01-31 |
| PT3672571T (pt) | 2021-11-02 |
| ES2895370T3 (es) | 2022-02-21 |
| US20210267988A1 (en) | 2021-09-02 |
| EP3672571A1 (en) | 2020-07-01 |
| US11541058B2 (en) | 2023-01-03 |
| JP7313126B2 (ja) | 2023-07-24 |
| JP2019038799A (ja) | 2019-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501794A1 (en) | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same | |
| IL252368B (en) | 2-(5,1-dimethyl-3-phenyl-h1-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2- Oxacetamide and pharmaceutical preparations containing it | |
| GB2572305B (en) | Heterocyclic urea compound, and drug composition and application thereof | |
| IL237378B (en) | Derivatives of 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl-5-(methyl-4,2,1,-triazole) and pharmaceutical compounds containing them | |
| IL246545B (en) | History of 3-hydroxy-3-[(cyclopropylmethoxy)-4-(fluoro)phenyl]-4-(h1- 3,2,1-triazol-1-yl)-butane and pharmaceutical preparations containing them | |
| EP3626709A4 (en) | INDAZOLE COMPOUND FOR USE IN INHIBITING KINASE ACTIVITY, COMPOSITION AND APPLICATION THEREOF | |
| IL247077B (en) | A pharmaceutical preparation containing a diamino heterocyclic carboxamide compound as an active ingredient | |
| IL279270A (en) | Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea | |
| IL273573A (en) | Nitrogen-containing heteroaryl compound and medicinal use thereof | |
| HRP20200104T8 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
| CY1124527T1 (el) | Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση | |
| LT3672571T (lt) | Farmacinė vandeninė vaisto forma, apimanti 1-(4-{[4-(dimetilamino)piperidin-1-il]karbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]karbamidą | |
| IL243650A0 (en) | History of 1-(piperazine-1-yl)-2-([4,2,1]triazol-1-yl)-ethanone | |
| PH12017502017A1 (en) | Pharmaceutical compositions | |
| WO2014105777A8 (en) | Cobicostat dichlohydrate salt | |
| IT201700098438A1 (it) | Testiera per cavalli | |
| IL257671A (en) | Salts of 1-(4-(2-((1-(4,3-difluorophenyl)-1h-pyrazol-3-yl(methoxy)ethyl)piperazin-1-yl)ethanone | |
| UA37000S (uk) | Диван кутовий «bruno» | |
| TH1601002081A (th) | รูปแบบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยโซเดียม 1-[6-(มอร์โฟลิน-4-อิล)ไพริมิดิน-4- อิล]-4-(1h-1,2,3-ไตรอะโซล-1-อิล)-1h-ไพราโซล-5-โอเลต | |
| UA33872S (uk) | Кутовий диван «renata» | |
| TH168885A (th) | อนุพันธ์ 1-(พิเพอราซิน-1-อิล)-2-([1,2,4]ไตรอะโซล-1-อิล)-เอทาโนน |